Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

MSK identified a new subtype of small cell lung cancer in young non-smokers, challenging existing treatment paradigms with ...

Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, ...

Extracellular vesicles (EVs) loaded with customizable anti-cancer antisense oligonucleotides suppressed cancer growth.

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

TD Cowen analyst Yaron Werber has maintained their bullish stance on IOBT stock, giving a Buy rating yesterday. Yaron Werber has given his Buy ...

BeyondSpring (BYSI) announced that phase 2 IIT data on the first 30 patients dosed with plinabulin in the 303 Study of patients with non-small cell lung cancer after disease ... 57% patients with ...